Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine M Hunt

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 16, 2019
Identifying and Treating Nonalcoholic Fatty Liver DiseaseChristine M Hunt, Marsha J Turner, Elizabeth J Gifford, et al.
Regulatory Toxicology and Pharmacology : RTP|October 12, 2010
The evaluation of drug rechallenge: the casopitant Phase III programChristine M Hunt, Julie I Papay, Donna S Rich, et al.
Pharmacoepidemiology and Drug Safety|December 22, 2012
Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record dataJanet Shin, Christine M Hunt, Ayako Suzuki, et al.
Regulatory Toxicology and Pharmacology : RTP|June 7, 2012
A pre-marketing ALT signal predicts post-marketing liver safetyCynthia A Moylan, Ayako Suzuki, Julie I Papay, et al.
Regulatory Toxicology and Pharmacology : RTP|July 1, 2008
Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver diseaseJohn G Weil, Chanchal Bains, Adam Linke, et al.
Military Medicine|October 19, 2016
Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013Julie Lynch, Scott L DuVall, Brygida Berse, et al.
Regulatory Toxicology and Pharmacology : RTP|November 8, 2011
Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver diseaseHeide A Stirnadel, Chanchal Bains, Mynepalli Lakshmi, et al.
Regulatory Toxicology and Pharmacology : RTP|March 24, 2009
Drug-induced liver injury following positive drug rechallengeJulie I Papay, Dawn Clines, Rezvan Rafi, et al.
Pharmacoepidemiology and Drug Safety|June 13, 2014
An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record dataT Craig Cheetham, Janet Lee, Christine M Hunt, et al.
Drug Safety|August 30, 2012
Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populationsXiwu Lin, Daniel Parks, Jeffery Painter, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 16, 2019
Identifying and Treating Nonalcoholic Fatty Liver DiseaseChristine M Hunt, Marsha J Turner, Elizabeth J Gifford, et al.
Regulatory Toxicology and Pharmacology : RTP|October 12, 2010
The evaluation of drug rechallenge: the casopitant Phase III programChristine M Hunt, Julie I Papay, Donna S Rich, et al.
Pharmacoepidemiology and Drug Safety|December 22, 2012
Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record dataJanet Shin, Christine M Hunt, Ayako Suzuki, et al.
Regulatory Toxicology and Pharmacology : RTP|June 7, 2012
A pre-marketing ALT signal predicts post-marketing liver safetyCynthia A Moylan, Ayako Suzuki, Julie I Papay, et al.
Regulatory Toxicology and Pharmacology : RTP|July 1, 2008
Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver diseaseJohn G Weil, Chanchal Bains, Adam Linke, et al.
Military Medicine|October 19, 2016
Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013Julie Lynch, Scott L DuVall, Brygida Berse, et al.
Regulatory Toxicology and Pharmacology : RTP|November 8, 2011
Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver diseaseHeide A Stirnadel, Chanchal Bains, Mynepalli Lakshmi, et al.
Regulatory Toxicology and Pharmacology : RTP|March 24, 2009
Drug-induced liver injury following positive drug rechallengeJulie I Papay, Dawn Clines, Rezvan Rafi, et al.
Pharmacoepidemiology and Drug Safety|June 13, 2014
An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record dataT Craig Cheetham, Janet Lee, Christine M Hunt, et al.
Drug Safety|August 30, 2012
Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populationsXiwu Lin, Daniel Parks, Jeffery Painter, et al.
Pageof 4